Missing ScriptStart HereBlogCountry ExplorerIntegrative Care GuideEvidence ExplorerPodcastAbout

Evidence Explorer / Evidence record

NUTRIENTS & SUPPLEMENTS

Creatine for cancer-related wasting and muscle loss

No demonstrated benefit

Creatine helps muscle performance in some healthy and aging populations, but the cancer trials have not established improvement in weight, lean mass, strength or function.

MS-N015 · Literature searched October 13, 2026 · Appraised October 13, 2026 · Cachexia / muscle function

Evidence at a glance

  • Largest direct trial: 263 evaluable people with incurable cancer and anorexia or weight loss were randomized to creatine or placebo.
  • Research regimen: 20 g/day for five days, then 2 g/day orally; this is not a personal prescription.
  • Primary endpoint: at least 10% weight gain in the first month occurred in 2 of 134 creatine recipients and 1 of 129 placebo recipients (P=1.00).
  • Other outcomes: appetite, quality of life, activities of daily living, grip strength and body composition did not differ; median survival was 230 versus 239 days (P=0.70).
  • 2026 synthesis: five randomized trials with 373 patients found no significant improvement in lean mass, strength, physical function or quality of life.

What the review adds

The 2026 review pooled heterogeneous trials lasting one to 12 weeks. Only two combined creatine with resistance training. Lean mass differed by 0.55 kg (95% CI −3.96 to 5.07), muscle strength SMD was −0.05 (95% CI −0.29 to 0.18), and physical function SMD was −0.20 (95% CI −0.68 to 0.28). These intervals include both possible benefit and no benefit. A pooled reduction in fat mass was reported, but losing fat is not evidence of reversing cachexia or restoring function.

Limits and uncertainty

The evidence is low-certainty because trials are small and populations, stages, doses and rehabilitation programs differ. The large negative trial used an ambitious 10% one-month weight-gain endpoint, but the absence of supporting changes in strength, body composition and quality of life makes a clinically important missed benefit less likely in that population. Results in healthy athletes cannot be assumed to transfer to inflammatory cancer cachexia.

Safety and practical context

Three of the five trials reported safety outcomes; only one specifically assessed kidney measures. Small, short studies cannot provide comprehensive safety reassurance during every cancer treatment. Creatine can cause water-related weight gain and gastrointestinal effects. Kidney disease, dehydration and nephrotoxic medicines warrant extra caution, and combination products may contain stimulants or other unstudied ingredients. Progressive weight loss should trigger nutrition, symptom and treatment-toxicity assessment rather than a supplement-only response.

Funding and conflicts: The 2026 review reported no funding; the authors’ full conflict statement was not clearly retrieved in this pass. Funding and conflict details for every component trial were not independently re-extracted.

Questions for the care team

  • Is the weight or muscle loss driven by inadequate intake, treatment toxicity, cachexia or a combination?
  • How will muscle and function be tracked alongside body weight?
  • Would oncology dietitian support and supervised resistance exercise address the goal more directly?
  • Could creatine complicate kidney monitoring or hydration management?

Sources

Learn how to judge a study · Return to the evidence map

This evidence brief is educational, not a personal treatment recommendation. Research regimens are not prescribing instructions. Symptom benefit does not establish tumor response, recurrence prevention or survival benefit.